Matching articles for "Deep vein thrombosis"
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • October 7, 2019; (Issue 1582)
Patients who receive pretravel advice can reduce their
risk for many travel-related conditions. Vaccines recommended
for travelers are reviewed in a separate...
Patients who receive pretravel advice can reduce their
risk for many travel-related conditions. Vaccines recommended
for travelers are reviewed in a separate issue.
Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
The Medical Letter on Drugs and Therapeutics • December 3, 2018; (Issue 1561)
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto –
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular...
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto –
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular events in
patients with chronic coronary artery disease (CAD)
or peripheral artery disease (PAD). Rivaroxaban is
the first direct oral anticoagulant to be approved for
this indication. It was approved earlier for prevention
and treatment of deep vein thrombosis (DVT) or
pulmonary embolism (PE) and for prevention of stroke
and systemic embolism in patients with nonvalvular
atrial fibrillation.
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • March 30, 2015; (Issue 1465)
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic...
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic embolism
in patients with nonvalvular atrial fibrillation. It is the
fourth new oral anticoagulant to be approved for VTE
and nonvalvular atrial fibrillation.
New Oral Anticoagulants for Acute Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • January 6, 2014; (Issue 1433)
Anticoagulants are the drugs of choice for treatment
of deep vein thrombosis (DVT) and pulmonary
embolism (PE), collectively referred to as venous
thromboembolism...
Anticoagulants are the drugs of choice for treatment
of deep vein thrombosis (DVT) and pulmonary
embolism (PE), collectively referred to as venous
thromboembolism (VTE).
Rivaroxaban (Xarelto) for Acute Coronary Syndrome
The Medical Letter on Drugs and Therapeutics • December 12, 2011; (Issue 1379)
The standard antithrombotic therapy for treatment of
patients with acute coronary syndrome (ACS) is dual
antiplatelet therapy with aspirin and clopidogrel (Plavix)
or another thienopyridine, plus a...
The standard antithrombotic therapy for treatment of
patients with acute coronary syndrome (ACS) is dual
antiplatelet therapy with aspirin and clopidogrel (Plavix)
or another thienopyridine, plus a parenteral anticoagulant
while the patient is hospitalized, followed by antiplatelet
therapy alone after discharge. The addition of the oral
anticoagulant warfarin (Coumadin, and others) to dual
antiplatelet therapy is generally not recommended for this
indication because of fluctuations in its anticoagulant
effect and the risk of bleeding. A recently published trial
found that addition of a low dose of the oral anticoagulant
rivaroxaban (Xarelto) to antiplatelet therapy after discharge
reduced the risk of major cardiovascular events
without increasing the incidence of fatal bleeding.
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • October 1, 2011; (Issue 110)
Arterial thrombi are composed mainly of platelet
aggregates held together by small amounts of fibrin.
Antiplatelet drugs are the drugs of choice for prevention
and treatment of arterial thrombosis, but...
Arterial thrombi are composed mainly of platelet
aggregates held together by small amounts of fibrin.
Antiplatelet drugs are the drugs of choice for prevention
and treatment of arterial thrombosis, but anticoagulants
are also effective, and their effects can add to those of
antiplatelet drugs. Venous thrombi are composed
mainly of fibrin and trapped red blood cells, with relatively
few platelets. Anticoagulants are the agents of
choice for prevention and treatment of venous thromboembolism
and for prevention of cardioembolic
events in patients with atrial fibrillation.
Rivaroxaban (Xarelto) - A New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • August 22, 2011; (Issue 1371)
The FDA has approved rivaroxaban (Xarelto –
Janssen), an oral direct factor Xa inhibitor, for prevention
of deep vein thrombosis (DVT) in patients undergoing
knee or hip replacement...
The FDA has approved rivaroxaban (Xarelto –
Janssen), an oral direct factor Xa inhibitor, for prevention
of deep vein thrombosis (DVT) in patients undergoing
knee or hip replacement surgery.
Desirudin (Iprivask) for DVT Prevention
The Medical Letter on Drugs and Therapeutics • November 1, 2010; (Issue 1350)
The injectable direct thrombin inhibitor desirudin (Iprivask – Canyon), a recombinant analog of hirudin,
the leech anticoagulant protein, was approved by the FDA in 2003 for prevention of venous...
The injectable direct thrombin inhibitor desirudin (Iprivask – Canyon), a recombinant analog of hirudin,
the leech anticoagulant protein, was approved by the FDA in 2003 for prevention of venous thromboembolism (VTE) after elective hip arthroplasty, but was only marketed recently in the US. It has been available in Europe as Revasc for about 10 years. Two other hirudin analogs are available in the US: lepirudin (Refludan) for treatment of heparin-induced thrombocytopenia (HIT) and bivalirudin (Angiomax) for use in percutaneous coronary intervention (PCI).
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • May 1, 2006; (Issue 45)
Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers...
Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel.
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • May 1, 2004; (Issue 21)
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for...
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control (CDC) at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel. Recommendations for the treatment of parasitic diseases are available in the public reading room of The Medical Letter's web site.
Tinzaparin, A Low Molecular Weight Heparin For Treatment of Deep Vein Thrombosis
The Medical Letter on Drugs and Therapeutics • February 19, 2001; (Issue 1098)
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein...
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein thrombosis.